United Therapeutics (UTHR) Long-Term Deferred Tax (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Long-Term Deferred Tax data on file, last reported at $335.4 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax fell 26.54% year-over-year to $335.4 million; the trailing twelve-month figure through Mar 2026 stood at $335.4 million (down 26.54% YoY), and the FY2025 full-year result was $357.7 million, down 21.97% from the prior year.
• Long-Term Deferred Tax retreated to $335.4 million in Q1 2026, from $357.7 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $458.4 million in Q4 2024 to a low of $271.8 million in Q1 2022.
• A 5-year average of $360.3 million and a median of $354.9 million in 2025 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax increased 25.12% in 2022 and slipped 26.54% in 2026, its largest moves.
• Tracing UTHR's Long-Term Deferred Tax over 5 years: stood at $327.7 million in 2022, then grew by 20.48% to $394.8 million in 2023, then rose by 16.11% to $458.4 million in 2024, then slipped by 21.97% to $357.7 million in 2025, then retreated by 6.23% to $335.4 million in 2026.
• Business Quant data shows UTHR's Long-Term Deferred Tax at $335.4 million in Q1 2026, $357.7 million in Q4 2025, and $354.9 million in Q3 2025.